Get the Stockscreener App
2.10
1.87%
-0.04
After Hours:
2.29
0.19
+9.05%
Connect Biopharma Holdings Ltd stock is traded at $2.10, with a volume of 189.76K.
It is down -1.87% in the last 24 hours and down -4.11% over the past month.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
See More
Previous Close:
$2.14
Open:
$2.15
24h Volume:
189.76K
Relative Volume:
0.53
Market Cap:
$132.22M
Revenue:
$233.00K
Net Income/Loss:
$-64.61M
P/E Ratio:
-1.8204
EPS:
-1.1536
Net Cash Flow:
$-58.32M
1W Performance:
-4.55%
1M Performance:
-4.11%
6M Performance:
-20.75%
1Y Performance:
-5.41%
1-Day Range:
$2.08
$2.20
1-Week Range:
$2.08
$2.245
52-Week Range:
$1.23
$3.82
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Name
Connect Biopharma Holdings Ltd
Sector
Industry
Phone
858-727-1040
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
2.10 | 134.74M | 233.00K | -64.61M | -58.32M | -1.1536 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Lake Street | Buy |
| Oct-31-25 | Initiated | BTIG Research | Buy |
| Jun-12-25 | Initiated | H.C. Wainwright | Buy |
| Mar-04-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Apr-13-21 | Initiated | Piper Sandler | Overweight |
| Apr-13-21 | Initiated | SVB Leerink | Outperform |
View All
Connect Biopharma Holdings Ltd Stock (CNTB) Latest News
Connect Biopharma Holdings Ltd (CNTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNTB|Connect Biopharma Holdings Ltd|Price:2.110|Chg%:-0.030 - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Balance Sheet - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Income Statement - TradingKey
CNTB|Connect Biopharma Holdings Ltd|Price:2.140|Chg%:-0.060 - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIO 2026: Catching Up With Vaxart, Aphaia, Connect Biopharma, Kyverna And Chugai - insights.citeline.com
Lake Street Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Oppenheimer Initiates Connect Biopharma(CNTB.US) With Buy Rating, Announces Target Price $8 - Moomoo
CNTB Initiates Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer initiates Connect Biopharma stock with outperform rating By Investing.com - Investing.com Nigeria
Oppenheimer initiates Connect Biopharma stock with outperform rating - Investing.com
CNTB Stock Price, Quote & Chart - ChartMill
CNTBConnect Biopharma Holdings Ltd Dividends - Finviz
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - MPNnow.com
Form 4 Connect Biopharma Holdings Ltd For: 1 July By Investing.com - Investing.com Canada
Connect Biopharma (CNTB) director granted 3,738 fully vested shares as fees - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director receives 6,718-share award as 2026 board compensation - Stock Titan
CCORF Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Connect Biopharma Holdings Limited(NasdaqGM: CNTB) added to Russell Microcap Index - marketscreener.com
Piper Sandler initiates Connect Biopharma stock with overweight rating By Investing.com - Investing.com Nigeria
Piper Sandler initiates Connect Biopharma stock with overweight rating - Investing.com
Connect Biopharma Holdings Ltd. Actuals & Estimates (NASDAQ:CNTB) - TradingView
H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 - Investing.com
Analysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN) - The Globe and Mail
Connect Biopharma Holdings Ltd (CNTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNTB Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 By Investing.com - Investing.com South Africa
Connect Biopharma Holdings Ltd - TradingKey
Connect Biopharma stock rises after Phase 2 asthma study enrollment - Investing.com
Connect Biopharma Holdings Ltd (CNTB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Institutional Confidence - TradingKey
Connect Biopharma Holdings Ltd (CNTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Connect Biopharma stock rises after Phase 2 asthma study enrollment By Investing.com - Investing.com South Africa
Connect Biopharma completes asthma trial enrollment By Investing.com - Investing.com South Africa
Connect Biopharma completes asthma trial enrollment - Investing.com
Connect Biopharma Announces Completion of Enrollment of - GlobeNewswire
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma - The Manila Times
Connect Biopharma touts Rademikibart's edge as SEABREEZE data looms in 2026 - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Tuesday’s insider activity: Big buys at Radian and MasterBrand - Investing.com
Connect Biopharma director James Huang acquires $371,610 in shares By Investing.com - Investing.com Australia
Connect Biopharma director James Huang acquires $371,610 in shares - Investing.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Director-linked fund boosts Connect Biopharma (NASDAQ: CNTB) stake - Stock Titan
[EFFECT] Connect Biopharma Holdings Ltd SEC Filing - Stock Titan
Connect Biopharma Holdings Ltd Stock (CNTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):